Top of this page
Skip navigation, go straight to the content
At UCB,
we aspire to be the patient-preferred biotech leader.
To achieve this goal, UCB has become an innovation-driven global biopharmaceutical company creating value for patients, the company, its shareholders and society in general.
Our work has an impact on the lives of many people. Every UCB employee is committed to follow the strict regulatory standards for research, development, manufacturing and distribution of our products to ensure we meet all safety, quality, regulatory, legal and environmental requirements.
In an ever-changing and more complex environment, UCB’s patient value strategy is the best route to achieve this ambition and long-term success.
2018 FY results
UCB will publish its 2018 full year results on Thursday 28 February 2019.
IR events›
| Date | Event details |
|---|---|
| 28 February 2019 | UCB 2018 full year resultsMore details in due course |
| 05 March 2019 | Credit Suisse London One-on-One Healthcare Conference, London1/1 meetings planned on 5 & 6 March |
| 19 March 2019 | Oppenheimer's 29th Annual Healthcare Conference, New York1/1 meetings planned on 19 & 20 March |
Outlook 2018
2018 revenue reporting to reach approximately
€ 4.5-4.6 billion
Recurring EBITDA [Operating profit adjusted for amortisation, depreciation, impairment charges, restructuring expenses and other exceptional income and expenses.] in the range of
€ 1.3-1.4 billion
Core earnings per share are therefore expected in the range of
€ 4.30-4.70
based on an average of
188 million shares outstanding
Contact UCB IR team
investor-relations@ucb.com or a specific team member:
- Antje Witte, VP Investor Relations
Tel: +32 2 559 9414
E-mail: Antje.Witte@ucb.com - Isabelle Ghellynck, Associate Director Investor Relations
Tel: +32 2 559 9588
E-mail: Isabelle.Ghellynck@ucb.com - Nathalie Deldime, Investor Relations Events Manager
Tel: +32 2 559 9291
E-mail: Nathalie.Deldime@ucb.com
UCB IR App
